Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study
| Autor: | Stylianos Kakolyris, S. Tzannes, E. Papadakis, V. Georgoulias, Ioanna Dimopoulou, A. Geroyianni, Papadimitriou Ca, John Souglakos, T. Georgopoulou, N. Vardakis, Nikos Androulakis, Athanasios Kotsakis, Dora Hatzidaki, Charalambos Kouroussis |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Vinorelbine Gastroenterology Deoxycytidine Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Survival rate Aged Salvage Therapy Chemotherapy business.industry Hematology Middle Aged medicine.disease Chemotherapy regimen Survival Analysis Gemcitabine Surgery Oncology Docetaxel Female business Progressive disease medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 9(10) |
| ISSN: | 0923-7534 |
| Popis: | Summary Background To evaluate the tolerance and efficacy of the combination of paclitaxel and gemcitabine as salvage treatment in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods Forty-nine patients with measurable NSCLC (PS 0–1: 80%; stage IV: 84%) who progressed or failed first-line chemotherapy were enrolled. Prior chemotherapy was cisplatin-based with (n = 20) or without (n = 22) docetaxel and docetaxel–vinorelbine (n = 7). Patients received gemcitabine (900 mg/m2 i.v.; days 1 and 8) and paclitaxel (175 mg/m2; day 8) every three weeks; G-CSF (150 μg/m2/day s.c; days 9–15) was given prophylactically to all patients. Results One (2%) complete and eight (16%) partial responses were achieved (overall response 18%; 95% CI: 4%–24%); 14 patients (29%) had stable disease and 26 (53%) progressive disease. Six responses were observed in 17 patients who responded to first-line chemotherapy. The median duration of response was seven months, the median TTP eight months and the median survival 11 months. The one-year survival rate was 37%. Grade 3–4 neutropenia occured in six (12%) patients, grade 2–3 neurotoxicity in 16 (32%) and grade 2–3 asthenia in 25 (51%). Other toxicities were mild. Conclusions The paclitaxel-gemcitabine combination is a well-tolerated and relatively active salvage regimen in patients with NSCLC and it merits further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|